Cytek Biosciences

Rising Costs And Trade Tensions Will Shrink Flow Cytometry Markets

AnalystLowTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

06 Sep 25

AnalystLowTarget's Fair Value

US$4.00

2.5% overvalued

06 Sep

US$4.10

-24.8%

-1.0%

-24.8%

-1.0%

Edit anytime before Sep 6 10:18 PM. Then post Updates to your followers.

Author's Valuation

US$4.0

2.5% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$4.0

2.5% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.19%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.28%

Calculation

US$33.71m

Earnings '28

17.87x

PE Ratio '28

US$602.48m

Market Cap '28

US$602.48m

Market Cap '28

122.58m

No. shares '28

US$4.92

Share Price '28

US$4.92 Share Price '28

Discounted to 2025 @ 7.28% p.a.

US$3.98

Fair Value '25